STCube

STCube Gross Margin

The Gross Margin of STCube (052020.KQ) as of Oct 24, 2026 is 25.54 %. In the previous year, Gross Margin was 10.59 % — a change of 141.22% (higher).

Gross Margin

25.54 %

YoY

141.22%

Last updated:

Gross Margin of STCube is 2025 25.54 % . Gross Margin of STCube was 2024 10.59 % . It decreases by 141.22% higher compared to the previous year.

STCube's gross margin stands at 25.5%, up from 16.9% several years earlier.

The STCube Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
2.38 KRW
Jan 1, 2019
48.44 KRW
Jan 1, 2020
16.22 KRW
Jan 1, 2021
16.94 KRW
Jan 1, 2022
26.09 KRW
Jan 1, 2023
26.76 KRW
Jan 1, 2024
10.59 KRW
Jan 1, 2025
25.54 KRW
The STCube Gross Margin history
YEARGross MarginYoY
25.54 %+141.22%
10.59 %-60.43%
26.76 %+2.57%
26.09 %+53.97%
16.94 %+4.47%
16.22 %-66.52%
48.44 %+1,938.59%
2.38 %-197.97%
-2.43 %-103.97%
61.03 %+2,371.38%
2.47 %+767.90%
0.28 %+481.67%
0.05 %-67.32%
0.15 %+25.32%
0.12 %+205.11%
0.04 %-79.31%
0.19 %+32.89%
0.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Gross Margin of STCube is 25.54 % in 2025.

Gross Margin of STCube changed from 10.59 % to 25.54 %, representing a 141.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin STCube since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's STCube with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — STCube

All Key Metrics — STCube